Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drug delivery devices market size is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the global drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications

Injectable drug delivery devices are used for various routes of drug administration such as intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular. The main types of injectable drug delivery devices are conventional injectable, pre-filled syringes, auto-injectors, and pen-injectors. The prefilled syringes are the packaging with the fixed needle that contains single-dose vaccines or other medications. The injectable drug delivery devices offer applications such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others that are used by various end-users such as hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others. The injectable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with a injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global injectable drug delivery devices market size will grow from $39.93 billion in 2022 to $43.54 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global injectable drug delivery devices market size is expected to grow from $58.1 billion in 2027 at a CAGR of 7.5%. The increasing preference for self-injection devices is driving the injectable drug delivery devices market. Self-injection devices are medical devices that can be used by the patient in-home setting for self-administration of the medication. Self-injection devices include needle-free, auto, pen, and wearable injectors. These self-injectables were developed to provide the most adaptable device which has a high precision of drug delivery and is easy to use. In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. BD Physioject is a disposable auto-injector, manufactured by Becton, Dickinson, and Company, which is clinically proven, reliable, and cost-effective specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma, and osteoporosis. The other companies currently involved in the self-injections market include Abbvie, Inc., 3M, Baxter, Gerresheimer AG, Pfizer Inc., and more. The advantages of self-injectable injections and increasing awareness of self-administration have increased the demand for self-injectable devices and will drive the injectable drug delivery devices market during the forecast period. The emergence of alternative drug delivery devices to injectable drug delivery devices is negatively affecting the market. Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery systems. There are many alternative (painless) drug delivery systems such as nasal, transdermal, transmucosal, vaginal, anal, and others that are evolving. The selection of a drug delivery system depends on the drug release, absorption, distribution, metabolism, and elimination profile of the therapeutic agent to achieve the highest level of safety and efficacy from the drug. Alternative drug delivery systems hold key importance in improving bioavailability, reducing toxicity, and safety elimination of drug which is administered to treat a particular disease. Growing disease-related complications, regular developments in drugs, and combinations of therapeutic agents are used to treat disease driving the need for alternative drug delivery systems. There are some recent ongoing developments in the field of alternative drug delivery systems mainly in a nanoparticles-based delivery system, intracellular delivery system, neural delivery system, and many more. Thus, the emergence of alternative drug delivery methods limits the growth of the injectable drug delivery devices market. The companies in injectable drug delivery devices are increasingly focusing on the manufacturing of auto-injectors. The auto-injectors are fully automated, highly customized, and reusable injectors that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during injection. These devices can adjust the speed and depth of the automatic injection. For instance, LISA, a reusable auto-injector manufactured by Unilife corporation comes with an array of highly customizable features including Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming for target therapies. The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches to improve the convenience and ease of administration of parenteral therapeutics. Major players in the injectable drug delivery devices market are Becton, Dickinson and Company, Gerresheimer AG, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Schott AG, Baxter International, Owen Mumford, Mylan N.V., and Sanofi. North America was the largest region in the injectable drug delivery devices market in 2022. Western Europe was the second-largest region in the global injectable drug delivery devices market. The regions in the global injectable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries included in the injectable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global injectable drug delivery devices market is segmented - 1) By Type: Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors 2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Other Applications 3) By End User: Hospitals And Clinics, Home Healthcare Settings, Pharmaceutical And Biotechnological Companies, Research Laboratories, Other End Users

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site specific drug delivery and require smaller doses, thereby minimising side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilise and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable drug delivery devices market grew from $18.35 billion in 2022 to $19.58 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable drug delivery devices market is expected to grow from $26 billion in 2027 at a CAGR of 7.3%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was one in three in 2020. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in June 2022, Medtronic plc recalled Cobalt XT, Cobalt, and Crome Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) for the reasons of reports of devices with a short circuit protection (SCP) alert resulting in reduced-energy electric shock delivery, instead of delivering a second phase of high voltage therapy. This may result in failure of device and irregular heartbeat which can lead to more serious issues. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In February 2022, Second Sight Medical Products, a California-based manufacturer of prosthetic devices, merged with Nano Precision Medical. The companies would collaborate to develop drug delivery medical implants.Nano Precision Medical is a US-based developer of NanoPortal drug implant technology. Major players in the implantable drug delivery devices market are Allergan Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck, Genetech Inc., and Psivida. North America was the largest region in the implantable drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global implantable drug delivery devices market report. The regions covered in the global implantable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications

A microneedle drug delivery system is a device with hundreds of microneedles on a patch that delivers a sufficient amount of drug in treatment. The main types of technologies in microneedle drug delivery systems are solid microneedle technology, hollow microneedle technology, dissolved microneedle technology, and others. Peptides are dried on the tips of a microneedles array in the solid microneedles method, which uses a coating of powerful chemicals. The solid microneedles are 250 micrometers to 700 micrometers in length and come in patch form that can be stored at room temperature. The microneedle drug delivery systems are used for drug delivery, vaccine delivery, others and employed in diagnostic laboratories, life sciences, research laboratories, hospitals, ambulatory surgical centers, and others. The microneedles drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides microneedles drug delivery systems market statistics, including microneedles drug delivery systems industry global market size, regional shares, competitors with a microneedles drug delivery systems market share, detailed microneedles drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the microneedles drug delivery systems industry. This microneedles drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microneedle drug delivery systems market size grew from $3.62 billion in 2022 to $4.07 billion in 2023 at a compound annual growth rate (CAGR) of 12.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The microneedle drug delivery systems market size is expected to grow to $7.84 billion in 2027 at a CAGR of 17.8%. The increase in research and demand for the vaccination process are predicted to drive the microneedle drug delivery systems market growth. Researchers view microneedle as an alternative way to inject vaccines where the receiver of the vaccine is expected to not feel any sensation of pain. Microneedle patches vaccine was developed initially for flu and measles; however, the technology is now being used increasingly for delivery of COVID-19 vaccine as well. For instance, in 2020, The University of Connecticut, Vaxess, and Verndari are using microneedles to deliver viral proteins into the skin, where they induce an immune response. According to a Bloomberg report, more than 3.98 billion doses of vaccine have been administered across 180 countries until July 2021. Increased demand from government and health research and development bodies for microneedle drug delivery technology propels the market for microneedle drug delivery systems going forward. Biodegradable microneedles drug delivery patches are increasingly used in local therapeutic gene delivery and treatment of chronic diseases. The use of biodegradable microneedles patches helps in easy and fast delivery of genes through targeting the skin as a site for local delivery. Gene delivery and treatment with these patches are easily accessible and contain fluid and lymph vessels that help the genetic material to act effectively. For instance, in 2020, a group from Terasaki Institute for Biomedical Innovation has recently worked on optimizing the release and performance of the biodegradable patches. Biodegradable microneedles patches offer several advantages in gene delivery such as improved efficacy, fast delivery, customized delivery, and others. In May 2020, Altaris Capital Partners, a US-based company acquired Kindeva Drug Delivery for $650 million. The deal is expected to help Altaris to develop and provide more innovative drug delivery technologies to the healthcare system by using the expertise of 3M and the Kindeva team. Kindeva Drug Delivery (Formerly known as 3M Drug Delivery Systems) is an American manufacturer of pharmaceutical and biotechnology products including inhalation, microneedle, and transdermal drug delivery technologies used for the treatment of cardio and respiratory health conditions. Major players in the microneedle drug delivery systems market are 3M, Zosano Pharma, Becton-Dickinson Technologies, Nanopass Technologies, Corium, Valeritas, Microdermics, TheraJect Inc., LTS Lohmann Therapie-Systeme AG, BioSerenTach (BT), Sorrento Therapeutics, Debiotech, Raphas Co. Ltd., QuadMedicine, SNvia, and NanoBiosciences. North America was the largest region in the microneedles drug delivery systems market in 2022. Europe was the second-largest region in the microneedles drug delivery systems market. The regions covered in the microneedles drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microneedle drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The microneedles drug delivery systems market consists of sales of hydrogel microneedles and dissolvable microneedle. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microneedle drug delivery systems market is segmented - 1) By Technology: Hollow, Porous, Solid, Other Technologies 2) By Application: Drug Delivery, Vaccine Delivery, Other Applications 3) By End-User: Diagnostics Laboratories, Life Sciences, Research Laboratories, Hospitals, Ambulatory Surgical Centers, Other End-Users

The topical drug delivery market refers to the procedure of delivering a drug from a product on the skin to a local target site to produce a therapeutic effect. Topical drug deliveries are used to provide medication that is applied to the skin to treat different conditions. The types of products in topical drug delivery are semi-solid formulations, liquid formulations, solid formulations, and transdermal products. Semi-solid formulations refer to a group of medications referred to as semi-solids, including creams, gels, ointments, suppositories, and other unique topical dose forms. The route of administration includes dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The various end users include hospitals, clinics, home healthcare, diagnostic centers, and other end users. The topical drug delivery market research report is one of a series of new reports from The Business Research Company that provides topical drug delivery market statistics, including topical drug delivery industry global market size, regional shares, competitors with a topical drug delivery market share, detailed topical drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the topical drug delivery industry. This topical drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global topical drug delivery market size grew from $137.93 billion in 2022 to $150.69 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The topical drug delivery market size is expected to grow to $210.39 billion in 2027 at a CAGR of 8.7%. The growing prevalence of diabetes is expected to propel the growth of the topical drug delivery market going forward. Diabetes is a group of diseases that affect how the body uses blood sugar and result in high blood sugar levels. Topical drug delivery helps diabetes patients by administering medicines that can bypass hepatic first-pass metabolism. For instance, in December 2021, according to the statistics published by International Diabetes Federation, a Belgium-based, non-profit diabetes association 2021, 537 million adults (20-79 years) recorded living with diabetes, and 6.7 million people died of diabetes in 2021. However, by 2030, it is anticipated that there will be 643 million people worldwide will have diabetes. Therefore, the growing prevalence of diabetes is driving the growth of the topical drug delivery market. Technological advancement is a key trend gaining popularity in the topical drug delivery market. Major companies operating in the topical drug delivery market are developing innovative products with advanced technologies to strengthen their position in the topical drug delivery market. For instance, in April 2022, Sol-Gel Technologies Ltd., an Israel-based dermatology company, and Galderma S.A., a Switzerland-based pharmaceutical company specializing in dermatological treatments and skin care products, introduced Epsolay (benzoyl peroxide, cream, 5%), utilizing Sol-Gel’s microencapsulation technology for the treatment of inflammatory lesions of rosacea, which is patent protected until 2040. Sol-gel microencapsulation provides the advantage of entrapping molecules by forming inclusion complexes between essential oils (Eos) as guest molecules and beta-cyclodextrin as host in porous silica, making it more stable and resistant to environmental conditions. Silica acts as a protector for EOs. In June 2022, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kedalion Therapeutics and its AcuStream technology for an undisclosed amount. This acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions. Kedalion Therapeutics is a US-based clinical-stage, venture-funded ophthalmic drug company operating in the topical drug delivery market. Major players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd., Galderma SA, Johnson & Johnson Private Limited, GlaxoSmithKline PLC., Bausch Health Companies Inc., Cipla Ltd., Bayer AG, 3M, Merck & Co., Inc., Crescita Therpeutics Inc., Novartis International AG, Taro Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Encore Dermatology Inc., Medpharm Group Limited, SkinVisible Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co., Inc., and Pfizer Inc. North America was the largest region in the topical drug delivery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topical drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the topical drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The topical drug delivery market includes revenues earned by entities by lotions, gels, patches, and powders. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global topical drug delivery market is segmented - 1) By Product Type: Semi-Solid Formulations, Liquid Formulations, Solid Formulations, Transdermal Products 2) By Route Of Administration: Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery, Nasal Drug Delivery 3) By End User: Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Other End Users

Liposomal drug delivery devices are microscopic colloidal spheres that are used to deliver drug molecules to the site of action. The main types of liposomal drug delivery devices are liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin is a kind of chemotherapy drug known as anthracycline wrapped up in a liposome. It slows or stops the increase of cancer cells by blocking an enzyme called topoisomerase. The applications included are fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy that are used in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and others. The liposomal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global liposomal drug delivery devices market grew from $4.1 billion in 2022 to $4.5 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The liposomal drug delivery devices market is expected to grow from $6.72 billion in 2027 at a CAGR of 10.6%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in radiation therapy, chemotherapy, and surgical resection. According to the American Cancer Society, there were 1.9million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the liposomal drug delivery devices market over the forthcoming years. The high cost of liposomal drug delivery devices is expected to limit the growth of the market during the forecast period. The high cost of devices makes liposomal treatment more expensive and unaffordable for patients, thereby hindering the growth of the market. For instance, according to the Journal of Biotechnology & Biomaterials, lipid/liposomal drug delivery systems are expensive to produce attributing to their high production cost. The high cost of products results from the high cost associated with the raw materials used in lipid excipients and the requirement of expensive equipment to increase manufacturing. Furthermore, according to the ScienceDirect Journal, liposomal drug delivery is the most expensive treatment for topical disorders such as psoriasis, atopic dermatitis, and skin cancer. Several big companies are undertaking various strategic initiatives such as collaborations and new product development, which is likely to become a major trend in the liposomal drug delivery devices market. Various companies are coming together to develop liposomal drug delivery systems to expand their product portfolio and operations worldwide. For instance, in 2021, MindMed is an Israeli creative drug development company, announced the execution of a Memorandum of Understanding regarding the introduction of an exclusive collaborative development program to optimize the supply of particular psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) supply technology, for which it has a license. In March 2020, FUJIFILM Corporation announced its decision to offer contract services of process development and manufacturing of liposome formulations to its partners seeking drug delivery formulations that are designed to deliver the therapeutic to the affected sites. In July 2020, Croda International, PLC., a UK-based specialty chemicals company, acquired Avanti Polar Lipids, Inc. for $260 million. The acquisition is expected to expand life sciences products, cGMP production capabilities, and pharmaceutical services for biotechnology, life science, and expand customers for Croda International. Avanti Polar Lipids Inc. is a USA-based company that specializes in lipid-based drug delivery technology for next-generation pharmaceuticals. Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde), Teva Pharmaceutical, and Sigma-Tau Group. North America was the largest region in the liposomal drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market report. The regions covered in the global liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the liposomal drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global liposomal drug delivery devices market is segmented - 1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types 2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy 3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users

Pharmaceutical drug delivery refers to the process or method of administering a drug to an animal or human to achieve a therapeutic effect. It is a formulation or apparatus that allows a medicinal material to target its site of action while avoiding nontarget cells, organs, or tissues. The main types of pharmaceutical drug delivery routes of administration are oral, ocular, pulmonary, nasal, injectable, topical, and other routes. The oral route refers to the administration of a drug through the mouth, which is the most common route for drug administration due to its sustained and controlled delivery, ease of administration, and feasibility for solid dosage forms. The different pharmaceutical drug delivery applications include infectious diseases, cancer, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. The different end-users include hospitals, home care settings, ASC/Clinics, and other end users. The pharmaceutical drug delivery market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug delivery market statistics, including pharmaceutical drug delivery industry global market size, regional shares, competitors with a pharmaceutical drug delivery market share, detailed pharmaceutical drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug delivery industry. This pharmaceutical drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharmaceutical drug delivery market size grew from $1597.53 billion in 2022 to $1752.39 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical drug delivery market size is expected to grow to $2075.25 billion in 2027 at a CAGR of 4.3%. The growing prevalence of chronic diseases is expected to propel the growth of the pharmaceutical drug delivery market going forward. Prevalence of chronic diseases refers to the total number of existing cases of chronic diseases in a population at a specific time. Pharmaceutical drug delivery helps the patients suffering from chronic diseases by delivering a pharmaceutical drug to a specific part of the body to treat different diseases. For instance, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, noncommunicable diseases kill 41 million people each year, equivalent to 71% of all deaths globally and cardiovascular diseases account for most of the deaths. Therefore, the growing prevalence of chronic diseases is driving the pharmaceutical drug delivery market. The adoption of nano-based drug delivery systems is a key trend gaining popularity in the pharmaceutical drug delivery market. The use of nanomaterials in pharmaceutical drug delivery can increase the cellular uptake of drugs because of the surface charge and time and they can increase the stability and water solubility of drugs. For instance, in March 2020, Bioavanta-Boston, a Switzerland-based chitosan nanoparticles research organization released Novochizol, unique polysaccharide nanotechnology that can be utilized to encapsulate any effective pharmaceutical additive such as a small molecule, or biologic for localized delivery and steady discharge in any organ or tissue, allowing for the treatment of severe COVID-19 infection in the lungs. In May 2022, Halozyme Therapeutics, a US-based biotechnology company acquired Antares Pharma for a deal amount of $960 million. With this acquisition, Halozyme targets to strengthen its position as a leading drug delivery company by including Antares specialty products. Antares Pharma is a US-based specialty pharmaceutical drug delivery company. Major players in the pharmaceutical drug delivery market are 3M Company, Bayer AG, Becton Dickinson And Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC., Johnson & Johnson Inc., Merck & Co Inc., Novartis AG, Pfizer Inc., Sanofi S.A., AbbVie Inc., Amgen Inc., AstraZeneca plc., Boehringer Ingelheim, Boston Scientific Corporation, Bristol-Myers Squibb, Consort Medical plc, Eli Lilly and Company, Emergent Biosolutions Inc., Kite Pharma, Nemera France SAS, Nimbus Therapeutics, SHL Medical AG., Teva Pharmaceuticals Industries Ltd., and West Pharmaceutical Services Inc., North America was the largest region in the pharmaceutical drug delivery market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this pharmaceutical drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The pharmaceutical drug delivery market includes revenues earned by entities by administering a pharmaceutical compound to achieve a therapeutic effect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drug delivery market is segmented - 1) By Route of Administration: Oral, Ocular, Pulmonary, Nasal, Injectable, Topical, Other Routes 2) By Application: Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases, Other Applications 3) By End-User: Hospitals, Home Care Settings, ASC/Clinics, Other End Users

Generic pharmaceuticals refer to a drug that was developed to have the same dosage form, safety, strength, mode of administration, quality, performance attributes, and intended use as an already marketed brand-name drug. The action and clinical benefits of a generic drug are identical to those of a brand-name drug. The three main types of generic pharmaceuticals are biosimilar; simple generic, and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectable, dermal/topical, and inhalers that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology. The various distribution channels involved is hospital pharmacies, retail pharmacies, and online pharmacies. The generic pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides generic pharmaceuticals market statistics, including generic pharmaceuticals industry global market size, regional shares, competitors with a generic pharmaceuticals market share, detailed generic pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the generic pharmaceuticals industry. This generic pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global generic pharmaceuticals market grew from $332.43 billion in 2022 to $358.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The generic pharmaceuticals market is expected to grow from $453.19 billion in 2027 at a CAGR of 6.0%. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceutical market. As more individuals are diagnosed with chronic diseases, they look for more medicines for treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost and have the same chemical composition as branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes on for a longer period, and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the number of deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world are due to chronic diseases. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceutical market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs, which are a substitute for expensive branded drugs. Thus, consumers opt for branded drugs even though the generic drugs carry the same chemical formulation as their counter-branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being at par with branded drugs. For example, according to research conducted by Sahana K Hebbar, in the International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, a lack of awareness about the availability of generic drugs hampers the generic pharmaceutical market. 3D printing technology can transform the manufacturing of drugs in the generic pharmaceutical market. 3D printed pharmaceuticals help improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customised size, shape, and texture, which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances, and tastes. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology, which manufactures 3D printed drugs. The drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in the manufacturing, packaging, and processing of drug products. Part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. In January 2020, ANI Pharmaceuticals, Inc., a USA-based integrated specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals, acquired Commercial and Pipeline Generic Products from American Pharmaceuticals, Ltd. for $52.5M in cash. This acquisition substantially increases ANI Pharmaceuticals, Inc.’s commercial portfolio and late-stage generic pipeline. Amerigen Pharmaceuticals is a USA-based company focused on the development, manufacture, and sale of high-quality generic pharmaceutical products. Major players in the generic pharmaceuticals market are Teva Pharmaceuticals, Mylan NV, Sandoz International GmbH, Hospira (Pfizer Inc.), Sun Pharmaceutical, Lupin Limited, Endo International PLC., Dr Reddy's Laboratories, Apotex Holdings, Fresenius Kabi Ag, Aurbindo Pharma, Aspen Pharmacare, Sanofi, Cipla, Hikma Pharmaceuticals, Stada Arzneimittel, Krka Group, Nichi-Iko Pharmaceutical, Valeant, Zydus Cadila, Merck & Co., Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Nexus Pharmaceuticals, Novo Nordisk, Ranbaxy Laboratories Ltd., Sawai Pharmaceuticals, Novartis AG, Pfizer and Johnson & Johnson Services. North America was the largest region in the generic pharmaceuticals market in 2022. The Middle East is expected to be the fastest-growing region in the global generic pharmaceuticals market during the forecast period. The regions covered in the global generic pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the generic pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The generic pharmaceuticals market consists of sales of paracetamol, cefixime, amoxicillin, and ofloxacin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global generic pharmaceuticals market is segmented - 1) By Therapy: CNS, Cardiovascular, Dermatology, Genitourinary/Harmonal, Respiratory, Rheumatology, Diabetes, Oncology 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Type: Biosimilar, Simple Generic, Super Generic 4) By Drug Delivery: Oral, Inectables, Dermal/Topical, Inhaler